Abstracts tagged "inflammatory myositis"

Abstract Number: 2152 • 2017 ACR/ARHP Annual Meeting
Mycophenolate Mofetil Treatment with or without a Calcineurin Inhibitor in Resistant Inflammatory Myopathy
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose : Patients with polymyositis (PM) and dermatomyositis (DM) refractory to glucocorticoid therapy have been treated with a variety of immunosuppressants including mycophenolate mofetil (MMF)…
Abstract Number: 2153 • 2017 ACR/ARHP Annual Meeting
Decreased Lean Body Mass and Bone Mineral Density but Increased Body Fat in Myositis Patients Are Associated with Disease Duration, Inflammatory Status, Skeletal Muscle Involvement and Physical Activity
Sabina Oreska¹, Maja Spiritovic^1,2, Petr Cesak², Ondrej Marecek², Hana Storkanova¹, Katerina Kubinova¹, Martin Klein¹, Lucia Vernerova¹, Olga Ruzickova¹, Radim Becvar¹, Karel Pavelka¹, Ladislav Senolt¹, Herman F Mann¹, Jiri Vencovsky¹ and Michal Tomcik¹, ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterized by inflammation and atrophy of skeletal muscles, pulmonary and articular involvement, which limit the mobility/self-sufficiency of patients, and…
Abstract Number: 276 • 2016 ACR/ARHP Annual Meeting
Histological Study on the Expression of Transcriptional Intermediary Factor 1 (TIF1) in the Patients with Idiopathic Inflammatory Myopathies
Young Kim¹, Jinhyun Kim², Seong-Wook Kang³, Seung Cheol Shim², In-Seol Yoo², Su-Jin Yoo¹ and Sung Hae Chang⁴, ¹Rheumatology, Daejeon Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Daejeon, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Daejeon Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Daejeon, Korea, The Republic of, ³Daejeon Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Gwangju, South Korea, ⁴Internal Medicine, Rheumatology, Soonchunhyang University, College of Medicine, Cheonan, South Korea
Background/Purpose: Myositis-specific antibodies in patients with inflammatory myopathies are known to be associated with various clinical manifestations, classifications and diagnosis. Among them, recently found anti-transcriptional…
Abstract Number: 282 • 2016 ACR/ARHP Annual Meeting
From ‘immune Mediated Necrotizing Myopathy’ to ‘antibody-Mediated Necrotizing Myositis: Towards the Pathogenic Role of Anti-SRP and Anti-Hmgcr Antibodies’
Yves Allenbach¹, Louiza Arouche-Delaperche², Corinna Preusse³, Gillian Butler Browne², Nicolas Champtiaux⁴, Kuberaka Mariampillai⁵, Aude Rigolet⁶, Peter Hufnagl⁷, Norman Zerbe⁸, Thierry Maisonobe⁹, Damien Amelin², Sarah Leonard-louis¹⁰, Charles Duyckaerts¹¹, Bruno Eymard¹², Hans-Hilmar Goebel³, Laurent Drouot¹³, Olivier Boyer¹⁴, Olivier Benveniste^2,5 and Werner Stenzel³, ¹Pitié-Salpêtrière University Hospital, AP-HP, Department of Internal Medicine and Clinical Immunology, Paris, France, Paris, France, ²Sorbonne Universités UPMC Univ Paris 06, Myology research center, INSERM UMRS974, CNRS FRE3617, Pitié-Salpêtrière University Hospital, Paris, France, Paris, France, ³Charité - Universitätsmedizin, Department of Neuropathology, Berlin, Germany, Berlin, Germany, ⁴Department de Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, France, ⁵Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), Paris, France, Paris, France, ⁶Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ⁷Pathology departmen, Charite Hospital, Berlin, Germany, ⁸Department of Pathology, Charite Hospital, Berlin, Germany, ⁹Pitié-Salpêtrière University Hospital, AP-HP, Department of Neuropathology, Paris, France, Paris, France, ¹⁰Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Department of Neuropathology, Paris, France, Paris, France, ¹¹Neuropathology, Pitie-Salpetriere Hospital, Paris, France, ¹²Department of Neurology, Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, France, ¹³Immunology, INSERM U905, University of Rouen, Rouen, France, ¹⁴Immunology, Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France
Background/Purpose: Immune mediated necrotizing myopathy (IMNM) has been recently added as a new entity among dermatomyositis, polymyositis and sporadic inclusion body myositis. IMNM is defined…
Abstract Number: 773 • 2016 ACR/ARHP Annual Meeting
Risk Factors for Severe Infections in Rituximab Treated Patients: Comparison of Systemic Lupus Erythematosus and Inflammatory Myositis
Cristiane Medeiros¹, Luciana Seguro², Fernando Henrique Carlos de Souza², Nadia E Aikawa³ and Eloisa Bonfa⁴, ¹Rheumatology, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Pediatric Rheumatology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology Divison, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil
Background/Purpose: The use of Rituximab (RTX) in patients with autoimmune diseases has been associated with an increased incidence of infection and risk factors for this…
Abstract Number: 2057 • 2013 ACR/ARHP Annual Meeting
Biomarker and Serologic Predictors Of Clinical Improvement After B Cell Depletion In Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) – The RIM (Rituximab in Myositis) Trial
Ann M. Reed¹, Cynthia S. Crowson², Molly S. Hein¹, Consuelo Lopez de Padilla³, Helen Khun², Rohit Aggarwal⁴, Dana P. Ascherman⁵, Marc C. Levesque⁶ and Chester V. Oddis⁷, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The aim of this study was to examine the longitudinal utility of a biomarker signature in conjunction with myositis autoantibodies (autoAbs) as biomarkers of…
Abstract Number: 2016 • 2013 ACR/ARHP Annual Meeting
Inflamamatory Myositis-Increased Incidence In Fire Department Of New York Firefighters After World Trade Center Exposure
Basit Qayyum¹, Michelle S Glaser^2,3, Nadia Jaber³, Rachel Zeig-Owens^2,3, Mayris P Webber^3,4, Anna Nolan^3,5, Kerry J Kelly³ and David J Prezant^3,6, ¹New York University School of Medicine, New York, NY, ²Medicine, Montefiore Medical Center, Bronx, NY, ³Bureau of Health Services Fire Department of New York, Brooklyn, NY, ⁴Medicine and Epideiology and Population Health, Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY, ⁵Medicine, New York University School of Medicine, New York, NY, ⁶Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Inflammatory myositis (IM) is extremely rare in white middle-aged males. Incidence rates in males ranging from 0.25 to 5 per million. We describe a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].